Research Analysts Issue Forecasts for ALDX Q3 Earnings

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) – Analysts at HC Wainwright cut their Q3 2026 earnings per share estimates for shares of Aldeyra Therapeutics in a note issued to investors on Monday, August 17th. HC Wainwright analyst M. Caufield now forecasts that the biotechnology company will post earnings of ($0.11) per share for the quarter, down from their previous estimate of ($0.08). The consensus estimate for Aldeyra Therapeutics’ current full-year earnings is ($0.43) per share. HC Wainwright also issued estimates for Aldeyra Therapeutics’ Q4 2026 earnings at ($0.13) EPS, FY2026 earnings at ($0.39) EPS, FY2027 earnings at ($0.16) EPS, FY2028 earnings at ($0.02) EPS and FY2029 earnings at $0.17 EPS.

A number of other analysts have also issued reports on ALDX. Weiss Ratings reissued a “sell (e+)” rating on shares of Aldeyra Therapeutics in a research note on Monday. Wall Street Zen downgraded shares of Aldeyra Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Aldeyra Therapeutics currently has a consensus rating of “Hold” and an average target price of $5.50.

Aldeyra Therapeutics Trading Down 0.6%

Aldeyra Therapeutics stock opened at $1.55 on Wednesday. The firm has a market capitalization of $93.51 million, a P/E ratio of -3.97 and a beta of 1.22. The stock has a fifty day moving average price of $1.80 and a 200 day moving average price of $2.53. Aldeyra Therapeutics has a 52 week low of $1.07 and a 52 week high of $6.17.

Aldeyra Therapeutics (NASDAQ:ALDX) last posted its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.09).

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. 683 Capital Management LLC lifted its stake in shares of Aldeyra Therapeutics by 86.6% during the fourth quarter. 683 Capital Management LLC now owns 1,530,000 shares of the biotechnology company’s stock worth $7,925,000 after purchasing an additional 710,000 shares in the last quarter. Renaissance Technologies LLC grew its stake in shares of Aldeyra Therapeutics by 146.6% in the first quarter. Renaissance Technologies LLC now owns 863,187 shares of the biotechnology company’s stock valued at $1,459,000 after buying an additional 513,187 shares in the last quarter. GSA Capital Partners LLP acquired a new stake in shares of Aldeyra Therapeutics in the second quarter valued at about $1,007,000. Hikari Power Ltd purchased a new stake in shares of Aldeyra Therapeutics during the 2nd quarter valued at about $43,000. Finally, Dimensional Fund Advisors LP raised its holdings in shares of Aldeyra Therapeutics by 1.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 624,170 shares of the biotechnology company’s stock valued at $1,055,000 after buying an additional 11,912 shares during the period. 59.71% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, CEO Todd C. Brady bought 250,000 shares of the firm’s stock in a transaction dated Wednesday, June 3rd. The stock was acquired at an average price of $1.67 per share, for a total transaction of $417,500.00. Following the acquisition, the chief executive officer owned 1,721,298 shares of the company’s stock, valued at $2,874,567.66. This trade represents a 16.99% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders own 11.80% of the company’s stock.

About Aldeyra Therapeutics

Aldeyra Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapies for immune-mediated diseases. The company’s research efforts center on targeted alkenals, a class of reactive aldehyde species that play a key role in inflammatory pathways. By selectively modulating these pathways, Aldeyra aims to address both ocular and systemic indications with high unmet medical need.

The company’s lead product candidate, reproxalap, is being investigated in several ophthalmic disorders, including dry eye disease, allergic conjunctivitis and non-infectious anterior uveitis.